Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
AG13958
CHF 0.00
In stock
SYN-1004-M0011 mgCHF 355.00
SYN-1004-M0055 mgCHF 702.00
SYN-1004-M01010 mgCHF 1'078.00
SYN-1004-M05050 mgINQ
SYN-1004-M100100 mgINQ
| Product Details | |
|---|---|
| Synonyms | AG-13958 |
| Product Type | Chemical |
| Properties | |
| Formula | C26H22FN7O |
| MW | 467.5 |
| CAS | 319460-94-1 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: VEGF | Kinase Group: RTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | LLMBCXVXEQNNJB-DHZHZOJOSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
AG13958 is a VEGF inhibitor that was in clinical development for treatment of age-related macular degeneration (AMD). The drug displays low water solubility and so far in trials delivery has been difficult needing direct injection to be truly effective and it varied by the species used because of species specific differences in eye circulation and vascularization. As a VEGF inhibitor AG13958 was targeted to FLT/TYK receptor inhibition.
Product References
- 2nd Ophthalmic Drug Development and Delivery Summit: M. Marra, et al.; Expert Opin. Drug Deliv. 4, 77 (2007)
Related Products
